Takeda Pharmaceutical Files 6-K for December 2024
Ticker: TKPHF · Form: 6-K · Filed: Dec 2, 2024 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Dec 2, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
Takeda filed its monthly 6-K, confirming its foreign private issuer status and Tokyo HQ.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on December 2, 2024, reporting as a foreign private issuer for the month of December 2024. The filing indicates Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan.
Why It Matters
This filing serves as an update for investors regarding Takeda's status as a foreign private issuer, providing essential information about its reporting obligations.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain new financial or operational information that would typically indicate a change in risk.
Key Players & Entities
- TAKEDA PHARMACEUTICAL COMPANY LIMITED (company) — Filer
- 0001395064-24-000169 (other) — Accession Number
- 001-38757 (other) — SEC File Number
- 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan (location) — Principal executive offices
FAQ
What type of filing is this Form 6-K?
This Form 6-K is a Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
What period does this Form 6-K cover?
This Form 6-K is for the month of December 2024.
What is Takeda Pharmaceutical Company Limited's SEC file number?
Takeda Pharmaceutical Company Limited's SEC file number is 001-38757.
Where are Takeda's principal executive offices located?
Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, 103-8668, Japan.
Does Takeda file its annual reports under Form 20-F or Form 40-F?
Takeda indicates it files its annual reports under cover of Form 20-F.
Filing Stats: 193 words · 1 min read · ~1 pages · Grade level 15.2 · Accepted 2024-12-02 06:00:40
Filing Documents
- form6k_120224.htm (6-K) — 11KB
- fy2024_ibr.htm (EX-99.1) — 18KB
- fy2024_ibr001.jpg (GRAPHIC) — 211KB
- fy2024_ibr002.jpg (GRAPHIC) — 256KB
- fy2024_ibr003.jpg (GRAPHIC) — 214KB
- fy2024_ibr004.jpg (GRAPHIC) — 126KB
- fy2024_ibr005.jpg (GRAPHIC) — 208KB
- fy2024_ibr006.jpg (GRAPHIC) — 120KB
- 0001395064-24-000169.txt ( ) — 1593KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date December 2, 2024 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller